董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ali Behbahani | 男 | Director | 49 | 11.43万美元 | 2.19 | 2025-11-12 |
| Nessan Bermingham | 男 | Chairman of the Board | 53 | 14.88万美元 | 13.65 | 2025-11-12 |
| Jean Franois Formela | 男 | Director | -- | 11.28万美元 | 2.19 | 2025-11-12 |
| Katharine Knobil | 女 | Director | 62 | 10.63万美元 | 0.90 | 2025-11-12 |
| Rachel Meyers | 女 | Director | -- | 10.53万美元 | 1.96 | 2025-11-12 |
| Ram Aiyar | -- | Chief Executive Officer, interim Chief Financial Officer,Principal Financial Officer,President and Director | -- | 311.96万美元 | 34.46 | 2025-11-12 |
| Timothy R. Pearson | 男 | Director | 58 | 12.13万美元 | 2.19 | 2025-11-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey Cerio | 男 | Senior Vice President, General Counsel and Corporate Secretary | -- | 157.85万美元 | 2.91 | 2025-11-12 |
| Todd Chappell | 男 | Chief Operating Officer | -- | 未披露 | 未持股 | 2025-11-12 |
| Loc Vincent | 男 | Chief Scientific Officer | -- | 157.31万美元 | 2.33 | 2025-11-12 |
| Ram Aiyar | -- | Chief Executive Officer, interim Chief Financial Officer,Principal Financial Officer,President and Director | -- | 311.96万美元 | 34.46 | 2025-11-12 |
董事简历
中英对照 | 中文 | 英文- Ali Behbahani
-
Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
Ali Behbahani has served as a member of Arcellx, Inc. board of directors since January 2015. Dr. Behbahani joined New Enterprise Associates (NEA), a venture capital firm, in 2007 and is currently a Partner and the Co Head of Healthcare. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. Dr. Behbahani has been a member of the board of directors of Black Diamond Therapeutics (Nasdaq: BDTX) since December 2018, CRISPR Therapeutics AG (Nasdaq: CRSP) since March 2015, Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) since April 2020, Nkarta, Inc. (Nasdaq: NKTX) since August 2015, Korro Bio, Inc. (Nasdaq: KRRO) since August 2019, and SpyGlass Pharma, Inc. (Nasdaq: SGP) since May 2019. Dr. Behbahani previously served as a member of the board of directors of CVRx, Inc. (Nasdaq: CVRX) from July 2013 to September 2024, Genocea Biosciences (Nasdaq: GNCA) from February 2018 to May 2022, Minerva Surgical, Inc. (Nasdaq: UTRS) from May 2011 to January 2024, Oyster Point Pharma (Nasdaq: OYST) from July 2017 to January 2023, and Adaptimmune Therapeutics Plc (Nasdaq: ADAP) from September 2014 to November 2025. Dr. Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. - Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
- Ali Behbahani has served as a member of Arcellx, Inc. board of directors since January 2015. Dr. Behbahani joined New Enterprise Associates (NEA), a venture capital firm, in 2007 and is currently a Partner and the Co Head of Healthcare. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. Dr. Behbahani has been a member of the board of directors of Black Diamond Therapeutics (Nasdaq: BDTX) since December 2018, CRISPR Therapeutics AG (Nasdaq: CRSP) since March 2015, Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) since April 2020, Nkarta, Inc. (Nasdaq: NKTX) since August 2015, Korro Bio, Inc. (Nasdaq: KRRO) since August 2019, and SpyGlass Pharma, Inc. (Nasdaq: SGP) since May 2019. Dr. Behbahani previously served as a member of the board of directors of CVRx, Inc. (Nasdaq: CVRX) from July 2013 to September 2024, Genocea Biosciences (Nasdaq: GNCA) from February 2018 to May 2022, Minerva Surgical, Inc. (Nasdaq: UTRS) from May 2011 to January 2024, Oyster Point Pharma (Nasdaq: OYST) from July 2017 to January 2023, and Adaptimmune Therapeutics Plc (Nasdaq: ADAP) from September 2014 to November 2025. Dr. Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine.
- Nessan Bermingham
-
Nessan Bermingham自2014年5月创立公司起担任公司总裁、首席执行官和董事。创立Intellia之前，Bermingham从2002年到2007年以及2012年到2014年在Atlas Venture（一家初创风险资本公司，专注于生物和药物发现技术投资）担任多个职位，最近的职位是担任风险合伙人。他从2007年到2008年担任Omega Fund Management（直接二级医疗基金）合伙人；2009年到2013年担任Bio Equity Capital LLC（一家医疗保健特殊公司）创始人和管理合伙人。Bermingham是Tal Medical（一家临床阶段医疗设备公司）创始首席执行官；之前曾在UBS AG任职，并担任Merck Serono独立董事和Harbor Antibodies董事。Bermingham持有北爱尔兰贝尔法斯特Queen's University 理学学士学位；Imperial College London分子生物学博士学位；是Baylor College of Medicine的Howard Hughes Associate Fellow研究员。
Nessan Bermingham has held various positions at Atlas Venture, an early stage venture capital firm focused on investments in biological and drug discovery technologies, including as venture partner and currently as an advisor. From 2007 to 2008 he was a partner at Omega Fund Management, a direct secondary healthcare fund, and from 2009 to 2013 he served as the founder and managing partner of Bio Equity Capital LLC, a healthcare focused special situations firm. Dr. Bermingham was the founding Chief Executive Officer of Tal Medical, a clinical stage medical device company and previously worked at UBS AG. Dr. Bermingham currently serves on the Board of Directors of the Alliance for Regenerative Medicine. Dr. Bermingham received his B.S. from Queen's University in Belfast, Northern Ireland, a Ph.D. in molecular biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. - Nessan Bermingham自2014年5月创立公司起担任公司总裁、首席执行官和董事。创立Intellia之前，Bermingham从2002年到2007年以及2012年到2014年在Atlas Venture（一家初创风险资本公司，专注于生物和药物发现技术投资）担任多个职位，最近的职位是担任风险合伙人。他从2007年到2008年担任Omega Fund Management（直接二级医疗基金）合伙人；2009年到2013年担任Bio Equity Capital LLC（一家医疗保健特殊公司）创始人和管理合伙人。Bermingham是Tal Medical（一家临床阶段医疗设备公司）创始首席执行官；之前曾在UBS AG任职，并担任Merck Serono独立董事和Harbor Antibodies董事。Bermingham持有北爱尔兰贝尔法斯特Queen's University 理学学士学位；Imperial College London分子生物学博士学位；是Baylor College of Medicine的Howard Hughes Associate Fellow研究员。
- Nessan Bermingham has held various positions at Atlas Venture, an early stage venture capital firm focused on investments in biological and drug discovery technologies, including as venture partner and currently as an advisor. From 2007 to 2008 he was a partner at Omega Fund Management, a direct secondary healthcare fund, and from 2009 to 2013 he served as the founder and managing partner of Bio Equity Capital LLC, a healthcare focused special situations firm. Dr. Bermingham was the founding Chief Executive Officer of Tal Medical, a clinical stage medical device company and previously worked at UBS AG. Dr. Bermingham currently serves on the Board of Directors of the Alliance for Regenerative Medicine. Dr. Bermingham received his B.S. from Queen's University in Belfast, Northern Ireland, a Ph.D. in molecular biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.
- Jean Franois Formela
-
Legacy Korro的联合创始人之一Jean Fran ois Formela自合并完成以来一直担任Korro Bio，Inc.董事会成员，此前自2018年11月起担任Legacy Korro董事会成员。Formela博士目前是Atlas Venture的合伙人，Atlas Venture是一家专注于生命科学的风险投资公司，他于1993年加入该公司。Formela博士是IFM Therapeutics的联合创始人和董事，并担任Ikena Oncology, Inc.（纳斯达克：IKNA）的董事，以及以下私营公司的董事：Sail Bio，Inc.、Triveni Bio，Inc.和Travin Bio，Inc.。Formela博士此前还曾担任Intellia Therapeutics, Inc.（TERM3）（纳斯达克：NTLA）、Spero治疗（纳斯达克：SPRO）、Scorpion Therapeutics，Inc.（被礼来 and Company收购）的董事，以及多家私营公司。Formela博士是美国麻省理工学院Brigham创新顾问委员会的成员，也是波士顿当代艺术学院的前受托人。福尔梅拉医生的职业生涯始于巴黎内克尔大学医院的急诊内科医生。他拥有巴黎大学医学院的医学博士学位和哥伦比亚大学的工商管理硕士学位。
Jean Franois Formela,one of Legacy Korro's co-founders, has served as a member of Korro Bio, Inc. board of directors since completion of the Merger, and previously served on Legacy Korro's board of directors since November 2018. Dr. Formela is currently a partner at Atlas Venture, a life sciences-focused venture capital firm, which he joined in 1993. Dr. Formela is a co-founder and director of IFM Therapeutics, and serves as a director of Ikena Oncology, Inc. (Nasdaq: IKNA), as well as a director of the following private companies: Sail Bio, Inc., Triveni Bio, Inc. and Travin Bio, Inc. Dr. Formela also previously served as a director of Intellia Therapeutics, Inc. (Nasdaq: NTLA), Spero Therapeutics (Nasdaq: SPRO), Scorpion Therapeutics, Inc. (acquired by Eli Lilly and Company), and several private companies. Dr. Formela is a member of the Mass General Brigham Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. Dr. Formela began his career as a physician practicing emergency medicine at Necker University Hospital in Paris. He holds an M.D. from the Paris University School of Medicine and an M.B.A. from Columbia University. - Legacy Korro的联合创始人之一Jean Fran ois Formela自合并完成以来一直担任Korro Bio，Inc.董事会成员，此前自2018年11月起担任Legacy Korro董事会成员。Formela博士目前是Atlas Venture的合伙人，Atlas Venture是一家专注于生命科学的风险投资公司，他于1993年加入该公司。Formela博士是IFM Therapeutics的联合创始人和董事，并担任Ikena Oncology, Inc.（纳斯达克：IKNA）的董事，以及以下私营公司的董事：Sail Bio，Inc.、Triveni Bio，Inc.和Travin Bio，Inc.。Formela博士此前还曾担任Intellia Therapeutics, Inc.（TERM3）（纳斯达克：NTLA）、Spero治疗（纳斯达克：SPRO）、Scorpion Therapeutics，Inc.（被礼来 and Company收购）的董事，以及多家私营公司。Formela博士是美国麻省理工学院Brigham创新顾问委员会的成员，也是波士顿当代艺术学院的前受托人。福尔梅拉医生的职业生涯始于巴黎内克尔大学医院的急诊内科医生。他拥有巴黎大学医学院的医学博士学位和哥伦比亚大学的工商管理硕士学位。
- Jean Franois Formela,one of Legacy Korro's co-founders, has served as a member of Korro Bio, Inc. board of directors since completion of the Merger, and previously served on Legacy Korro's board of directors since November 2018. Dr. Formela is currently a partner at Atlas Venture, a life sciences-focused venture capital firm, which he joined in 1993. Dr. Formela is a co-founder and director of IFM Therapeutics, and serves as a director of Ikena Oncology, Inc. (Nasdaq: IKNA), as well as a director of the following private companies: Sail Bio, Inc., Triveni Bio, Inc. and Travin Bio, Inc. Dr. Formela also previously served as a director of Intellia Therapeutics, Inc. (Nasdaq: NTLA), Spero Therapeutics (Nasdaq: SPRO), Scorpion Therapeutics, Inc. (acquired by Eli Lilly and Company), and several private companies. Dr. Formela is a member of the Mass General Brigham Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. Dr. Formela began his career as a physician practicing emergency medicine at Necker University Hospital in Paris. He holds an M.D. from the Paris University School of Medicine and an M.B.A. from Columbia University.
- Katharine Knobil
-
Katharine Knobil，此前于2021年4月至2024年1月担任实验室产品和软件公司安捷伦科技公司的首席医疗官。此前，Knobil博士曾于2018年12月至2021年1月在Kaleido Biosciences, Inc.担任首席医疗官兼研发主管，该公司是一家临床阶段的医疗保健公司，目标是利用微生物组治疗疾病和改善健康。Knobil博士在制药公司葛兰素史克（GSK）担任越来越多的职责20多年，最近于2017年12月至2018年12月担任公司首席医疗官，负责监督制药、疫苗和消费者业务的医疗事务、健康结果、全球临床安全和医疗治理。此前，她曾于2015年11月至2017年12月担任GSK制药部门的首席医疗官，在此之前，她担任高级副总裁、价值证据和结果。Knobil博士于1997年首次加入GSK，担任呼吸临床开发的研究医师，随后担任多个职务，包括领导欧洲呼吸临床团队，以及在中国建设所有治疗领域的后期临床开发。Knobil博士被FiercePharma评为2018年生命科学领域最激烈的女性之一。Knobil博士目前担任Marker Therapeutics, Inc.（纳斯达克：MRKR）的董事会成员，自2021年12月起担任Pliant Therapeutics, Inc.（纳斯达克：PLRX）的董事会成员，自2022年9月起担任Nimbus Therapeutics，LLC的董事会成员，自2024年2月起担任Infinant Health，Inc.的董事会成员，自2025年3月起担任。从2020年6月到2022年3月，她一直是阿里那制药公司的董事会成员，直到该公司被辉瑞收购。Knobil博士获得了康奈尔大学的学士学位、得克萨斯大学西南医学院的医学博士学位，并在约翰霍普金斯医学院完成了肺部和重症医学的研究金。
Katharine Knobil joined the Board in December 2021. Dr. Knobil currently serves as Chief Medical Officer at Altesa BioSciences, Inc. and previoly served as Chief Medical Officer of Agilent Technologies Inc., a position she held from April 2021 to January 2024. Dr. Knobil previoly served as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, Inc. from December 2018 to January 2021. Previoly, Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline plc, most recently serving as the corporate Chief Medical Officer from 2017 to December 2018, and as Chief Medical Officer for Pharmaceuticals at GSK from 2015 to 2017. She served as a member of the board of directors of Arena Pharmaceuticals, Inc. from June 2020 until its acquisition by Pfizer Inc. in March 2022. Dr. Knobil currently serves on the Board of Directors of Nimb Therapeutics, LLC, KorroBio, Inc. and Pliant Therapeutics, Inc. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southstern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School. - Katharine Knobil，此前于2021年4月至2024年1月担任实验室产品和软件公司安捷伦科技公司的首席医疗官。此前，Knobil博士曾于2018年12月至2021年1月在Kaleido Biosciences, Inc.担任首席医疗官兼研发主管，该公司是一家临床阶段的医疗保健公司，目标是利用微生物组治疗疾病和改善健康。Knobil博士在制药公司葛兰素史克（GSK）担任越来越多的职责20多年，最近于2017年12月至2018年12月担任公司首席医疗官，负责监督制药、疫苗和消费者业务的医疗事务、健康结果、全球临床安全和医疗治理。此前，她曾于2015年11月至2017年12月担任GSK制药部门的首席医疗官，在此之前，她担任高级副总裁、价值证据和结果。Knobil博士于1997年首次加入GSK，担任呼吸临床开发的研究医师，随后担任多个职务，包括领导欧洲呼吸临床团队，以及在中国建设所有治疗领域的后期临床开发。Knobil博士被FiercePharma评为2018年生命科学领域最激烈的女性之一。Knobil博士目前担任Marker Therapeutics, Inc.（纳斯达克：MRKR）的董事会成员，自2021年12月起担任Pliant Therapeutics, Inc.（纳斯达克：PLRX）的董事会成员，自2022年9月起担任Nimbus Therapeutics，LLC的董事会成员，自2024年2月起担任Infinant Health，Inc.的董事会成员，自2025年3月起担任。从2020年6月到2022年3月，她一直是阿里那制药公司的董事会成员，直到该公司被辉瑞收购。Knobil博士获得了康奈尔大学的学士学位、得克萨斯大学西南医学院的医学博士学位，并在约翰霍普金斯医学院完成了肺部和重症医学的研究金。
- Katharine Knobil joined the Board in December 2021. Dr. Knobil currently serves as Chief Medical Officer at Altesa BioSciences, Inc. and previoly served as Chief Medical Officer of Agilent Technologies Inc., a position she held from April 2021 to January 2024. Dr. Knobil previoly served as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, Inc. from December 2018 to January 2021. Previoly, Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline plc, most recently serving as the corporate Chief Medical Officer from 2017 to December 2018, and as Chief Medical Officer for Pharmaceuticals at GSK from 2015 to 2017. She served as a member of the board of directors of Arena Pharmaceuticals, Inc. from June 2020 until its acquisition by Pfizer Inc. in March 2022. Dr. Knobil currently serves on the Board of Directors of Nimb Therapeutics, LLC, KorroBio, Inc. and Pliant Therapeutics, Inc. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southstern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School.
- Rachel Meyers
-
Rachel Meyers，2020年6月至2023年1月担任Faze Medicines，Inc.创始人兼首席科学官。在加入Faze Medicines之前，Meyers博士曾在Third Rock Ventures担任常驻企业家。从2003年4月到2016年11月，她还在Alynlam Pharmaceuticals，Inc.工作了超过13年，并且仍然是科学顾问委员会的活跃成员。迈耶斯博士还在多个科学顾问委员会任职，包括通过商务部设立的国家创新和创业顾问委员会。雷切尔在许多专利和专利申请中被列为发明人，并有许多同行评审的出版物。Meyers博士在哈佛医学院完成了信号转导领域的博士后培训，并在麻省理工学院获得了体外转录领域的博士学位。
Rachel Meyers,served as the Founder and Chief Scientific Officer at Faze Medicines, Inc. from June 2020 to January 2023. Prior to Faze Medicines, Dr. Meyers served as Entrepreneur-in-Residence at Third Rock Ventures. She also spent over 13 years at Alynlam Pharmaceuticals, Inc. from April 2003 to November 2016 and remains an active member of the scientific advisory board. Dr. Meyers also serves on several scientific advisory boards, including the National Advisory Board on Innovation and Entrepreneurship through the Department of Commerce. Rachel is listed as an inventor on many patents and patent applications, and has numerous peer-reviewed publications. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction and received her Ph.D. at the Massachusetts Institute of Technology in the field of in vitro transcription. - Rachel Meyers，2020年6月至2023年1月担任Faze Medicines，Inc.创始人兼首席科学官。在加入Faze Medicines之前，Meyers博士曾在Third Rock Ventures担任常驻企业家。从2003年4月到2016年11月，她还在Alynlam Pharmaceuticals，Inc.工作了超过13年，并且仍然是科学顾问委员会的活跃成员。迈耶斯博士还在多个科学顾问委员会任职，包括通过商务部设立的国家创新和创业顾问委员会。雷切尔在许多专利和专利申请中被列为发明人，并有许多同行评审的出版物。Meyers博士在哈佛医学院完成了信号转导领域的博士后培训，并在麻省理工学院获得了体外转录领域的博士学位。
- Rachel Meyers,served as the Founder and Chief Scientific Officer at Faze Medicines, Inc. from June 2020 to January 2023. Prior to Faze Medicines, Dr. Meyers served as Entrepreneur-in-Residence at Third Rock Ventures. She also spent over 13 years at Alynlam Pharmaceuticals, Inc. from April 2003 to November 2016 and remains an active member of the scientific advisory board. Dr. Meyers also serves on several scientific advisory boards, including the National Advisory Board on Innovation and Entrepreneurship through the Department of Commerce. Rachel is listed as an inventor on many patents and patent applications, and has numerous peer-reviewed publications. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction and received her Ph.D. at the Massachusetts Institute of Technology in the field of in vitro transcription.
- Ram Aiyar
-
Ram Aiyar，自2020年11月起担任Legacy Korro的首席执行官和董事，自2021年11月起担任其总裁。在加入Legacy Korro之前，Aiyar博士与他人共同创立了Corvidia Therapeutics，Inc.，最近于2020年1月至2020年11月担任其首席财务官，并于2016年2月至2020年11月担任公司和业务发展执行副总裁。在此之前，Aiyar博士曾在BeneVir BioPharma，Inc.、BioHealth Innovation，Inc.、FlowMetric，Inc.、Sofinnova Partners、J.P. Morgan Chase和强生制药公司（纽约证券交易所代码：JNJ）担任企业发展、产品开发、管理、研究、财务和战略方面的领导职务。Aiyar博士是Protean Bio，Inc.的联合创始人和董事，Triveni Bio，Inc.的董事和Avidea Technologies，Inc.的前任董事。Aiyar博士拥有INSEAD（法国/新加坡）的金融和商业战略工商管理硕士学位，Drexel大学的计算机工程硕士学位和电气和计算机工程博士学位，以及孟买大学的电子工程学士学位。
Ram Aiyar,served as Chief Executive Officer and as a director of Legacy Korro since November 2020, and has served as its President since November 2021. Prior to joining Legacy Korro, Dr. Aiyar co-founded Corvidia Therapeutics, Inc. and most recently served its as Chief Financial Officer from January 2020 to November 2020 and Executive Vice President, Corporate and Business Development from February 2016 to November 2020. Prior to that, Dr. Aiyar held leadership roles in corporate development, product development, management, research, finance and strategy at BeneVir BioPharma, Inc., BioHealth Innovation, Inc., FlowMetric, Inc., Sofinnova Partners, J.P. Morgan Chase and Johnson & Johnson Pharmaceuticals (NYSE:JNJ). Dr. Aiyar is a co-founder and director of Protean Bio, Inc., a director of Triveni Bio, Inc. and a past director of Avidea Technologies, Inc. Dr. Aiyar holds an M.B.A. in finance and business strategy from INSEAD (France/Singapore), an M.S. in computer engineering and a Ph.D. in electrical and computer engineering from Drexel University, and a B.E. in electronics engineering from Mumbai University. - Ram Aiyar，自2020年11月起担任Legacy Korro的首席执行官和董事，自2021年11月起担任其总裁。在加入Legacy Korro之前，Aiyar博士与他人共同创立了Corvidia Therapeutics，Inc.，最近于2020年1月至2020年11月担任其首席财务官，并于2016年2月至2020年11月担任公司和业务发展执行副总裁。在此之前，Aiyar博士曾在BeneVir BioPharma，Inc.、BioHealth Innovation，Inc.、FlowMetric，Inc.、Sofinnova Partners、J.P. Morgan Chase和强生制药公司（纽约证券交易所代码：JNJ）担任企业发展、产品开发、管理、研究、财务和战略方面的领导职务。Aiyar博士是Protean Bio，Inc.的联合创始人和董事，Triveni Bio，Inc.的董事和Avidea Technologies，Inc.的前任董事。Aiyar博士拥有INSEAD（法国/新加坡）的金融和商业战略工商管理硕士学位，Drexel大学的计算机工程硕士学位和电气和计算机工程博士学位，以及孟买大学的电子工程学士学位。
- Ram Aiyar,served as Chief Executive Officer and as a director of Legacy Korro since November 2020, and has served as its President since November 2021. Prior to joining Legacy Korro, Dr. Aiyar co-founded Corvidia Therapeutics, Inc. and most recently served its as Chief Financial Officer from January 2020 to November 2020 and Executive Vice President, Corporate and Business Development from February 2016 to November 2020. Prior to that, Dr. Aiyar held leadership roles in corporate development, product development, management, research, finance and strategy at BeneVir BioPharma, Inc., BioHealth Innovation, Inc., FlowMetric, Inc., Sofinnova Partners, J.P. Morgan Chase and Johnson & Johnson Pharmaceuticals (NYSE:JNJ). Dr. Aiyar is a co-founder and director of Protean Bio, Inc., a director of Triveni Bio, Inc. and a past director of Avidea Technologies, Inc. Dr. Aiyar holds an M.B.A. in finance and business strategy from INSEAD (France/Singapore), an M.S. in computer engineering and a Ph.D. in electrical and computer engineering from Drexel University, and a B.E. in electronics engineering from Mumbai University.
- Timothy R. Pearson
-
Timothy R. Pearson自2014年3月起担任公司董事。Pearson自2014年5月起担任TESARO, Inc.（一家专注于肿瘤学的生物制药公司）首席财务官。他还从2011年8月起担任Catalyst Health Solutions（一家制药利益管理公司）执行副总裁和首席财务官，一直担任到2012年7月该公司被SXC Health Solutions收购。加入Catalyst Health Solutions之前，Pearson从2007年到2011年担任MedImmune（AstraZeneca PLC一家全球生物企业）首席财务官和执行副总裁；他也是MedImmune执行小组成员。Pearson于1998年加入MedImmune，2007年被提升为首席财务官，在此之前一直担任金融副总裁和财务主管。Pearson还曾担任MedImmune Ventures（MedImmune的风险资本基金，对初期生物技术公司进行投资）创始人和投资委员会成员。Pearson是一名注册会计师，持有特拉华大学工商管理学士学位、Loyola College金融硕士学位和马里兰大学学院会计学学士学位。他也是一名注册会计师。
Timothy R. Pearson serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, Mr. Pearson served as Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc. from August 2011 to July 2012 where he led the finance and strategic planning functions. Prior to that, Mr. Pearson wasExecutive Vice President and Chief Financial Officer of MedImmune, the biologics division of AstraZeneca. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College. He is also a Certified Public Accountant. - Timothy R. Pearson自2014年3月起担任公司董事。Pearson自2014年5月起担任TESARO, Inc.（一家专注于肿瘤学的生物制药公司）首席财务官。他还从2011年8月起担任Catalyst Health Solutions（一家制药利益管理公司）执行副总裁和首席财务官，一直担任到2012年7月该公司被SXC Health Solutions收购。加入Catalyst Health Solutions之前，Pearson从2007年到2011年担任MedImmune（AstraZeneca PLC一家全球生物企业）首席财务官和执行副总裁；他也是MedImmune执行小组成员。Pearson于1998年加入MedImmune，2007年被提升为首席财务官，在此之前一直担任金融副总裁和财务主管。Pearson还曾担任MedImmune Ventures（MedImmune的风险资本基金，对初期生物技术公司进行投资）创始人和投资委员会成员。Pearson是一名注册会计师，持有特拉华大学工商管理学士学位、Loyola College金融硕士学位和马里兰大学学院会计学学士学位。他也是一名注册会计师。
- Timothy R. Pearson serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, Mr. Pearson served as Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc. from August 2011 to July 2012 where he led the finance and strategic planning functions. Prior to that, Mr. Pearson wasExecutive Vice President and Chief Financial Officer of MedImmune, the biologics division of AstraZeneca. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College. He is also a Certified Public Accountant.
高管简历
中英对照 | 中文 | 英文- Jeffrey Cerio
Jeffrey Cerio，自2024年8月起担任高级副总裁、总法律顾问和公司秘书。Cerio博士最近于2021年10月至2024年8月担任Atomwise Inc.的总法律顾问和公司秘书。他此前曾于2019年11月至2021年8月在Triplet Therapeutics，Inc.担任高级副总裁、总法律顾问和公司秘书。在此之前，他于2018年6月至2019年11月在Moderna, Inc.（纳斯达克：MRNA）担任证券高级公司法律顾问。在担任此职务之前，Cerio博士是阿尔凯默斯 PLC（纳斯达克：ALKS）的证券和业务发展顾问，在此之前是Ropes & Gray LLP的合伙人。Cerio博士拥有东北大学的药学博士学位和康涅狄格大学法学院的法学博士学位。
Jeffrey Cerio,has served as Senior Vice President, General Counsel and Corporate Secretary since August 2024. Dr. Cerio most recently served as General Counsel and Corporate Secretary at Atomwise Inc. from October 2021 to August 2024. He previously served as Senior Vice President, General Counsel and Corporate Secretary at Triplet Therapeutics, Inc. from November 2019 to August 2021. Prior to that he served as Senior Corporate Counsel, Securities at Moderna, Inc. (Nasdaq: MRNA) from June 2018 to November 2019. Prior to this role, Dr. Cerio was securities and business development counsel at Alkermes plc (Nasdaq: ALKS), and prior to that was an associate at Ropes & Gray LLP. Dr. Cerio holds a Pharm.D. from Northeastern University and a J.D. from the University of Connecticut School of Law.- Jeffrey Cerio，自2024年8月起担任高级副总裁、总法律顾问和公司秘书。Cerio博士最近于2021年10月至2024年8月担任Atomwise Inc.的总法律顾问和公司秘书。他此前曾于2019年11月至2021年8月在Triplet Therapeutics，Inc.担任高级副总裁、总法律顾问和公司秘书。在此之前，他于2018年6月至2019年11月在Moderna, Inc.（纳斯达克：MRNA）担任证券高级公司法律顾问。在担任此职务之前，Cerio博士是阿尔凯默斯 PLC（纳斯达克：ALKS）的证券和业务发展顾问，在此之前是Ropes & Gray LLP的合伙人。Cerio博士拥有东北大学的药学博士学位和康涅狄格大学法学院的法学博士学位。
- Jeffrey Cerio,has served as Senior Vice President, General Counsel and Corporate Secretary since August 2024. Dr. Cerio most recently served as General Counsel and Corporate Secretary at Atomwise Inc. from October 2021 to August 2024. He previously served as Senior Vice President, General Counsel and Corporate Secretary at Triplet Therapeutics, Inc. from November 2019 to August 2021. Prior to that he served as Senior Corporate Counsel, Securities at Moderna, Inc. (Nasdaq: MRNA) from June 2018 to November 2019. Prior to this role, Dr. Cerio was securities and business development counsel at Alkermes plc (Nasdaq: ALKS), and prior to that was an associate at Ropes & Gray LLP. Dr. Cerio holds a Pharm.D. from Northeastern University and a J.D. from the University of Connecticut School of Law.
- Todd Chappell
Todd Chappell自合并以来一直担任首席运营官，此前自2023年8月起担任Legacy Korro的首席运营官，此前自2021年3月起担任Legacy Korro的战略和投资组合规划高级副总裁。在加入Legacy Korro之前，Chappell先生于2019年6月至2021年3月期间担任Rasio Therapeutics，Inc.的首席执行官。在担任这一职务之前，他曾于2015年6月至2019年5月担任Perceptive Navigation，LLC的首席执行官。Chappell先生曾作为BioHealth Innovation，Inc.的常驻企业家管理过一系列初创制药和医疗设备公司。在此之前，Chappell先生是Shape Pharmaceuticals，Inc.的运营副总裁，Shape Pharmaceuticals，Inc.是HealthCare Ventures，LLC的投资组合公司，负责监督开发用于皮肤t细胞淋巴瘤的新型HDAC抑制剂的所有日常运营。在担任这一职务之前，Chappell先生是CombinatoRx，Inc.新产品的执行董事，在那里他领导了从分析阶段到人体临床研究的三个项目的推进。Chappell先生拥有波士顿大学的工商管理硕士学位和加州大学洛杉矶分校的生物学学士学位。
Todd Chappell,has served as Chief Operating Officer since the Merger and previously served as Chief Operating Officer of Legacy Korro since August 2023 and previously served as Senior Vice President, Strategy and Portfolio Planning of Legacy Korro from March 2021. Before joining Legacy Korro, Mr. Chappell served as Chief Executive Officer of Rasio Therapeutics, Inc. from June 2019 until March 2021. Prior to this role, he served as Chief Executive Officer of Perceptive Navigation, LLC from June 2015 until May 2019. Mr. Chappell previously managed a portfolio of start-up pharmaceutical and medical device companies as an entrepreneur-in-residence at BioHealth Innovation, Inc. Prior to that, Mr. Chappell was a Vice President of Operations at Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations for the development of a novel HDAC inhibitor for cutaneous t-cell lymphoma. Prior to this role, Mr. Chappell was an Executive Director of New Products at CombinatoRx, Inc., where he led the advancement of three programs from assay stage into human clinical studies. Mr. Chappell holds an M.B.A. from Boston University and a B.S. in biology from the University of California, Los Angeles.- Todd Chappell自合并以来一直担任首席运营官，此前自2023年8月起担任Legacy Korro的首席运营官，此前自2021年3月起担任Legacy Korro的战略和投资组合规划高级副总裁。在加入Legacy Korro之前，Chappell先生于2019年6月至2021年3月期间担任Rasio Therapeutics，Inc.的首席执行官。在担任这一职务之前，他曾于2015年6月至2019年5月担任Perceptive Navigation，LLC的首席执行官。Chappell先生曾作为BioHealth Innovation，Inc.的常驻企业家管理过一系列初创制药和医疗设备公司。在此之前，Chappell先生是Shape Pharmaceuticals，Inc.的运营副总裁，Shape Pharmaceuticals，Inc.是HealthCare Ventures，LLC的投资组合公司，负责监督开发用于皮肤t细胞淋巴瘤的新型HDAC抑制剂的所有日常运营。在担任这一职务之前，Chappell先生是CombinatoRx，Inc.新产品的执行董事，在那里他领导了从分析阶段到人体临床研究的三个项目的推进。Chappell先生拥有波士顿大学的工商管理硕士学位和加州大学洛杉矶分校的生物学学士学位。
- Todd Chappell,has served as Chief Operating Officer since the Merger and previously served as Chief Operating Officer of Legacy Korro since August 2023 and previously served as Senior Vice President, Strategy and Portfolio Planning of Legacy Korro from March 2021. Before joining Legacy Korro, Mr. Chappell served as Chief Executive Officer of Rasio Therapeutics, Inc. from June 2019 until March 2021. Prior to this role, he served as Chief Executive Officer of Perceptive Navigation, LLC from June 2015 until May 2019. Mr. Chappell previously managed a portfolio of start-up pharmaceutical and medical device companies as an entrepreneur-in-residence at BioHealth Innovation, Inc. Prior to that, Mr. Chappell was a Vice President of Operations at Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations for the development of a novel HDAC inhibitor for cutaneous t-cell lymphoma. Prior to this role, Mr. Chappell was an Executive Director of New Products at CombinatoRx, Inc., where he led the advancement of three programs from assay stage into human clinical studies. Mr. Chappell holds an M.B.A. from Boston University and a B.S. in biology from the University of California, Los Angeles.
- Loc Vincent
Lo c Vincent，自2025年3月起担任首席科学官。Vincent博士最近于2021年8月至2025年3月担任Affini-T Therapeutics的首席科学官。在担任此职务之前，他曾于2020年1月至2021年8月在武田担任肿瘤药物发现部门和免疫学部门负责人，于2019年4月至2019年12月在武田担任研究伙伴关系免疫肿瘤和细胞治疗发现副总裁，并于2016年11月至2019年3月在武田担任肿瘤学和免疫学研究伙伴关系负责人。Vincent博士拥有鲁昂大学药理学博士学位，并获得贝当古-舒勒基金会颁发的青年科学家奖。他在美国康奈尔大学威尔医学院开展肿瘤学博士后研究。
Loc Vincent,served as Chief Scientific Officer since March 2025. Dr. Vincent most recently served as Chief Scientific Officer at Affini-T Therapeutics from August 2021 to March 2025. Prior to this role, he served as Head, Oncology Drug Discovery Unit & Immunology Unit at Takeda from January 2020 to August 2021, Vice President, Immuno-Oncology & Cell Therapy Discovery, Research Partnerships at Takeda from April 2019 to December 2019 and Head, Oncology & Immunology Research Partnerships at Takeda from November 2016 to March 2019. Dr. Vincent holds a Ph.D. in pharmacology from the University of Rouen and received the Young Scientist Award from the Bettencourt-Schueller's Foundation. He carried out his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University.- Lo c Vincent，自2025年3月起担任首席科学官。Vincent博士最近于2021年8月至2025年3月担任Affini-T Therapeutics的首席科学官。在担任此职务之前，他曾于2020年1月至2021年8月在武田担任肿瘤药物发现部门和免疫学部门负责人，于2019年4月至2019年12月在武田担任研究伙伴关系免疫肿瘤和细胞治疗发现副总裁，并于2016年11月至2019年3月在武田担任肿瘤学和免疫学研究伙伴关系负责人。Vincent博士拥有鲁昂大学药理学博士学位，并获得贝当古-舒勒基金会颁发的青年科学家奖。他在美国康奈尔大学威尔医学院开展肿瘤学博士后研究。
- Loc Vincent,served as Chief Scientific Officer since March 2025. Dr. Vincent most recently served as Chief Scientific Officer at Affini-T Therapeutics from August 2021 to March 2025. Prior to this role, he served as Head, Oncology Drug Discovery Unit & Immunology Unit at Takeda from January 2020 to August 2021, Vice President, Immuno-Oncology & Cell Therapy Discovery, Research Partnerships at Takeda from April 2019 to December 2019 and Head, Oncology & Immunology Research Partnerships at Takeda from November 2016 to March 2019. Dr. Vincent holds a Ph.D. in pharmacology from the University of Rouen and received the Young Scientist Award from the Bettencourt-Schueller's Foundation. He carried out his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University.
- Ram Aiyar
Ram Aiyar，自2020年11月起担任Legacy Korro的首席执行官和董事，自2021年11月起担任其总裁。在加入Legacy Korro之前，Aiyar博士与他人共同创立了Corvidia Therapeutics，Inc.，最近于2020年1月至2020年11月担任其首席财务官，并于2016年2月至2020年11月担任公司和业务发展执行副总裁。在此之前，Aiyar博士曾在BeneVir BioPharma，Inc.、BioHealth Innovation，Inc.、FlowMetric，Inc.、Sofinnova Partners、J.P. Morgan Chase和强生制药公司（纽约证券交易所代码：JNJ）担任企业发展、产品开发、管理、研究、财务和战略方面的领导职务。Aiyar博士是Protean Bio，Inc.的联合创始人和董事，Triveni Bio，Inc.的董事和Avidea Technologies，Inc.的前任董事。Aiyar博士拥有INSEAD（法国/新加坡）的金融和商业战略工商管理硕士学位，Drexel大学的计算机工程硕士学位和电气和计算机工程博士学位，以及孟买大学的电子工程学士学位。
Ram Aiyar,served as Chief Executive Officer and as a director of Legacy Korro since November 2020, and has served as its President since November 2021. Prior to joining Legacy Korro, Dr. Aiyar co-founded Corvidia Therapeutics, Inc. and most recently served its as Chief Financial Officer from January 2020 to November 2020 and Executive Vice President, Corporate and Business Development from February 2016 to November 2020. Prior to that, Dr. Aiyar held leadership roles in corporate development, product development, management, research, finance and strategy at BeneVir BioPharma, Inc., BioHealth Innovation, Inc., FlowMetric, Inc., Sofinnova Partners, J.P. Morgan Chase and Johnson & Johnson Pharmaceuticals (NYSE:JNJ). Dr. Aiyar is a co-founder and director of Protean Bio, Inc., a director of Triveni Bio, Inc. and a past director of Avidea Technologies, Inc. Dr. Aiyar holds an M.B.A. in finance and business strategy from INSEAD (France/Singapore), an M.S. in computer engineering and a Ph.D. in electrical and computer engineering from Drexel University, and a B.E. in electronics engineering from Mumbai University.- Ram Aiyar，自2020年11月起担任Legacy Korro的首席执行官和董事，自2021年11月起担任其总裁。在加入Legacy Korro之前，Aiyar博士与他人共同创立了Corvidia Therapeutics，Inc.，最近于2020年1月至2020年11月担任其首席财务官，并于2016年2月至2020年11月担任公司和业务发展执行副总裁。在此之前，Aiyar博士曾在BeneVir BioPharma，Inc.、BioHealth Innovation，Inc.、FlowMetric，Inc.、Sofinnova Partners、J.P. Morgan Chase和强生制药公司（纽约证券交易所代码：JNJ）担任企业发展、产品开发、管理、研究、财务和战略方面的领导职务。Aiyar博士是Protean Bio，Inc.的联合创始人和董事，Triveni Bio，Inc.的董事和Avidea Technologies，Inc.的前任董事。Aiyar博士拥有INSEAD（法国/新加坡）的金融和商业战略工商管理硕士学位，Drexel大学的计算机工程硕士学位和电气和计算机工程博士学位，以及孟买大学的电子工程学士学位。
- Ram Aiyar,served as Chief Executive Officer and as a director of Legacy Korro since November 2020, and has served as its President since November 2021. Prior to joining Legacy Korro, Dr. Aiyar co-founded Corvidia Therapeutics, Inc. and most recently served its as Chief Financial Officer from January 2020 to November 2020 and Executive Vice President, Corporate and Business Development from February 2016 to November 2020. Prior to that, Dr. Aiyar held leadership roles in corporate development, product development, management, research, finance and strategy at BeneVir BioPharma, Inc., BioHealth Innovation, Inc., FlowMetric, Inc., Sofinnova Partners, J.P. Morgan Chase and Johnson & Johnson Pharmaceuticals (NYSE:JNJ). Dr. Aiyar is a co-founder and director of Protean Bio, Inc., a director of Triveni Bio, Inc. and a past director of Avidea Technologies, Inc. Dr. Aiyar holds an M.B.A. in finance and business strategy from INSEAD (France/Singapore), an M.S. in computer engineering and a Ph.D. in electrical and computer engineering from Drexel University, and a B.E. in electronics engineering from Mumbai University.